Roberto De Luca | Head of Therapeutic Antibodies
Philochem

Roberto De Luca graduated in Biology at ETH Zürich. He performed his PhD studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of tumors. Dr. De Luca is author of several peer-reviewed publications in international scientific journals.

Appearances:

Festival of Biologics Day 1 @ 14:40

Engineering Antibody-Cytokine Fusion Proteins (Immunocytokines) for Cancer Therapy

Immunocytokines can increase the therapeutic index of the cytokine payload
Immunocytokines can selectively localize at the tumor site
Immunocytokines can induce potent anticancer activity either alone or in combination with other immunomodulatory drugs

Roberto De Luca, Head of Therapeutic Antibodies, Philochem

last published: 01/Aug/25 16:05 GMT

back to speakers